BRISTOL MYERS SQUIBB Business Summary

Bristol Myers Squibb (BMS) is a global biopharmaceutical leader that generates revenue through the discovery, development, and sale of innovative medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. The company’s business model is currently centered on a transition from its "Legacy Portfolio"—which includes mature blockbusters like Eliquis, Opdivo, and Revlimid—to a "Growth Portfolio" featuring newer therapies such as Camzyos, Sotyktu, and the neuroscience asset Cobenfy. As of early 2026, the company is executing a multi-year strategy to mitigate the impact of patent expirations and the Inflation Reduction Act by integrating major acquisitions like Karuna Therapeutics, RayzeBio, and Mirati Therapeutics. BMS competes directly with Merck & Co., Pfizer, Johnson & Johnson, and AstraZeneca. While Merck’s Keytruda remains a formidable competitor in immuno-oncology, BMS maintains a top-tier position in cardiovascular health and is aggressively scaling its presence in cell therapy and radiopharmaceuticals to secure sustainable growth into the 2030s. The company is led by Board Chair and CEO Christopher Boerner, PhD, who succeeded Giovanni Caforio in 2023 and brings a pedigree from Genentech and Seattle Genetics. The core executive team includes David Elkins as Chief Financial Officer, Cristian Massacesi as Chief Medical Officer, and Greg Meyers as Chief Digital & Technology Officer. This leadership group oversees an annual R&D budget exceeding $9 billion and a workforce of approximately 34,000. The Board of Directors is chaired by Boerner with Theodore R. Samuels serving as Lead Independent Director; other notable members include cardiologist Dr. Deepak L. Bhatt and GE Healthcare CEO Peter J. Arduini. Originally formed by the 1989 merger of Bristol-Myers and E.R. Squibb & Sons, BMS is a publicly traded entity (NYSE: BMY) with significant institutional ownership from firms such as Vanguard and BlackRock, reflecting its status as a foundational healthcare investment.